- Home
- A-Z Publications
- Current Cancer Drug Targets
- Previous Issues
- Volume 22, Issue 2, 2022
Current Cancer Drug Targets - Volume 22, Issue 2, 2022
Volume 22, Issue 2, 2022
-
-
Experimental Determination of Cancer Drug Targets with Independent Mechanisms of Resistance
Authors: Abigail R. Bland, Nensi Shrestha, Maddie Berry, Christabel Wilson and John C. AshtonMathematical modelling of tumour mutation dynamics has suggested that cancer drug targets that have different resistance mechanisms should be good candidates for combination treatment. This is because the development of mutations that cause resistance to all drugs at once should arise relatively infrequently. However, it is difficult to identify drug targets fulfilling this requirement for particular cancers. Here we pres Read More
-
-
-
Pharmacological Targeting of Ferroptosis in Cancer Treatment
Ferroptosis is a non-apoptotic mode of Regulated Cell Death (RCD) driven by excessive accumulation of toxic lipid peroxides and iron overload. Ferroptosis could be triggered by inhibiting the antioxidant defense system and accumulating iron-dependent Reactive Oxygen Species (ROS) that react with polyunsaturated fatty acids in abundance. Emerging evidence over the past few years has revealed that ferroptosis is of grea Read More
-
-
-
CEA-regulated Oncolytic Virus Anticancer Therapy: A Promising Strategy for Rare Solid Tumors
Authors: Yuqi Yang, Shuhang Wang, Peiwen Ma, Qiyu Tang, Yandong Li, Yuan Fang, Qi Zhu, Wei Tao, Yan Zha and Ning LiBackground: Rare solid tumors have attracted much more attention due to the great unmet clinical need, limited treatment options, and poor prognosis. As the most thoroughly studied tumor marker, carcinoembryonic antigen (CEA) can not only overexpress in various common solid tumors but also in several rare solid tumors. Oncolytic virus therapy has achieved excellent anticancer effects in the past decades. Due t Read More
-
-
-
Preparation of Modified Chitosan-based Nanoparticles for Efficient Delivery of Doxorubicin and/or Cisplatin to Breast Cancer Cells
Authors: Sina M. Matalqah, Khalid Aiedeh, Nizar M. Mhaidat, Karem H. Alzoubi and Belal A. AL-HuseinPurpose: The aim is to develop a novel pH-responsive modified chitosan-based nanoparticles system for active loading of doxorubicin (DOX) and triggered intracellular release. Methods: Nanoparticles were formed in an aqueous medium via ionic interaction between negatively charged chitosan derivative and positively charged DOX at neutral pH and then transformed in situ into cisplatin (CIS) cross-linked nanoparticles t Read More
-
-
-
Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and in vitro Studies
Authors: Wei Shi, Lu Qi, Xiong-Bin You, Yu-Chi Chen, Yu-Lian Xu, Wei-Bang Yu, Mu-Yang Huang, Hong Zhao and Jin-Jian LuBackground: Shenling Baizhu Powder (SBP), a famous Traditional Chinese Medicine (TCM) formulation, has been widely used in the adjuvant treatment of cancers, including breast cancer. This study aims to identify potential new targets for breast cancer treatment based on the network pharmacology of SBP. Methods: By analyzing the relationship between herbs and target proteins, potential targets of multiple herbs in S Read More
-
-
-
Promotion of Cervical Cancer Cell Proliferation by miR-130b Expression Level Changes and Inhibition of its Apoptosis by Targeting CDKN1A Gene
Authors: Yanli Wang, Lei Yang, Caihong Fan, Hong Mu, Munan Han, Tao Liu, Lili Xie and Qiang GaoBackground: Dysregulation of miR-130b expression is associated with the development of different cancers. However, the description of the biological roles of miR-130b in the growth and survival of cervical cancer cells is limited. Methods: The miR-130b levels in cervical cancer cells during different stages of growth were determined using reverse transcription-quantitative PCR. The methylation level of DNA sequence Read More
-
-
-
The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers
Authors: Haneen A. Basheer, Lina Elsalem, Anwar Salem, Artysha Tailor, Keith Hunter and Kamyar AfarinkiaBackground: The increased glutamine metabolism is a characteristic feature of cancer cells. The interconversion between glutamine and glutamate is catalyzed by two glutaminase isoforms, GLS1 and GLS2, which appear to have different roles in different types of cancer. We investigated for the first time the protein expression of GLS1 and GLS2, and their correlation with advanced clinicopathological parameters in head and neck Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
-
Volume 5 (2005)
-
Volume 4 (2004)
-
Volume 3 (2003)
-
Volume 2 (2002)
-
Volume 1 (2001)
Most Read This Month
Article
content/journals/ccdt
Journal
10
5
false
en
